Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Centocor ( CNTO ) -- Ignore unavailable to you. Want to Upgrade?

To: FNS who wrote (520)	1/29/1998 4:54:00 AM
From: Todd D. Wiener	Respond to of 965

Centocor Up 15% On FDA's Decision On Cor's Integrilin Dow Jones Newswires NEW YORK -- Shares of Centocor Inc. (CNTO) rose sharply in late-afternoon trading Wednesday after a Food and Drug Administration panel said it will recommend approval for a limited use of competitor COR Therapeutics Inc.'s (CORR) anti-clotting drug Integrilin. The panel recommended Integrilin be approved for use in preventing clots in patients undergoing angioplasty. However, the panel rejected the company's attempt to win a recommendation for Integrilin's use in treating unstable angina. The full FDA generally, but not always, follows the advice of its expert panels. COR's Integrilin will compete with Centocor's ReoPro, which can be used to treat regular and low-risk angioplasty patients, as well as patients with refractory unstable angina who are scheduled for surgery within 24 hours, according to Bill Newbould, a Centocor spokesman. If Integrilin had received approval for both indications it would have beat ReoPro to the market, he said. ReoPro has been on the market for three years to treat high-risk angioplasty patients, but received expanded FDA approval in November 1997. Centocor shares rose 5, or 14.5%, to 39 3/8 on Nasdaq volume of 3.5 million, compared with average daily volume of 1.9 million. COR's drug will be co-marketed with drug-maker Schering-Plough Corp. (SGP) ReoPro is marketed by Eli Lilly & Co. (LLY). -Jennifer Fron Mauer; 201-938-5287; jennifer-fron.mauer@cor.dowjones.com